| INTRODUCTION
Traditionally, the potency of inactivated influenza vaccines has been determined using the single radial immunodiffusion (SRID) assay, an agarose gel-based format that uses strain-specific polyclonal antibody reagents to quantify the amount of influenza hemagglutinin (HA) present in a vaccine sample by comparison with the assigned HA value of a reference antigen standard. [1] [2] [3] The SRID assay is relatively simple and practical, strain-specific, and has acceptable accuracy and robustness for current vaccines. However, the dynamic range of the SRID is limited, the assay may not be ideal for newer types of influenza vaccines, and the assay requires large amounts of calibrated reagents that must be produced in a timely manner to support vaccine manufacturing. The latter issue is always a concern, both in the context of seasonal influenza vaccine manufacturing, as well as in the response to the emergence of a pandemic influenza strain. 4 Indeed, difficulties were encountered in the preparation of the SRID potency antisera for the A(H1N1)pdm09 pandemic vaccine and for candidate vaccines made in response to the emergence of the A(H7N9) virus in China in 2013. 5 In an attempt to address some of the limitations of the SRID, several newer methods have been explored in recent years as possible alternative potency assays for inactivated influenza vaccines. [6] [7] [8] [9] [10] [11] [12] [13] Several of these assays rely on the use of strain-specific 
| MATERIALS AND METHODS

| Cells and viruses
| Production of influenza H7 monoclonal antibodies
Purified murine mAbs to A/Shanghai/2/2013 HA were prepared as previously described, 17 
| Selection of escape mutants
The selection of A(H7N9) escape virus mutants 18 was performed by incubating A/Shanghai/2/2013 virus with H7 mAbs over a range of concentrations from 40 to 0.156 μg/mL, selecting resistant virus, and repeating the process for up to 2 more rounds of selection. Escape mutants were sequenced and tested for reduced inhibition of neutralization by the mAb compared to the parent virus.
| Measurement of potency by mAb ELISA
Potency ELISAs were performed as previously described. 12 Purified capture mAbs were used at a concentration of 2-4 μg/mL (determined empirically for each mAb to optimize antigen capture and minimize non-specific background 
| Measurement of potency by single radial immunodiffusion
The SRID assay was performed as previously described. 19, 20 Vaccine potency was calculated using the parallel line bioassay method, which uses reference and test vaccine dose-response curves (log antigen dilution versus log zone diameter). Replicates were included in each SRID assay, and assays were repeated on different days.
| Biolayer interferometry
Epitope binning and vaccine potency determination by BLI were per- concentration was optimized by initially diluting the mAb to 10 μg/ mL followed by twofold serial dilution before loading onto the AMC biosensor. Reference antigen, diluted to 30 μg/mL, was bound to the different concentrations of mAb, and the optimal mAb binding concentration was determined by selecting the highest mAb concentration at which the binding curves were not overlapping. For mAbs 1E9, 7B5, and 98, the optimal mAb concentration was determined to be 0.3 μg/mL. For mAb 5A6, an optimal concentration of 0.128 μg/mL was determined.
For vaccine potency determination, the AMC biosensors were dipped into buffer (baseline step) for 60 seconds, followed by loading the optimized mAb concentration for 300 seconds (load step). The biosensors were then dipped into the baseline buffer again, followed by the reference standard for 300 seconds (association step). A separate set of biosensors was used to repeat this process, except that the association steps used vaccine samples. The reference antigen and vaccine samples were prepared as a twofold dilution series with a starting concentration of approximately 30 μg/mL. All steps were performed at 23°C at a shake speed of 400 rpm. The HA concentration of vaccine samples was calculated by comparing the standard curve of the reference antigen to the standard curve generated for each vaccine sample. The same read time was used for both the reference and the vaccine sample being compared (20-300 seconds), and an unweighted dose-response 4PL curve was used for both the reference and the vaccine samples. Three replicates of standards and unknowns were included on each plate, and each assay repeated a minimum of two times on different days.
| RESULTS
| Isolation and characterization of monoclonal antibodies to the influenza H7 hemagglutinin
In a previous study, we described the isolation and characterization of murine mAbs to the H7 HA of the recently emerged A(H7N9) viruses in China, 17 but interestingly, all of the mAbs isolated in that study were directed to antigenic site A. In order to broaden the H7 HA epitope representation of our mAbs, we generated and characterized additional panels of mAbs using approaches designed to select for mAbs directed to epitopes other than antigenic site A.
In addition, we evaluated some existing mAbs (mAbs 62 and 98)
developed to an older H7N1 strain to determine how well these mAbs would bind the more recent A(H7N9) hemagglutinins. 21, 22 Monoclonal antibodies were assessed for binding to HA in an ELISA using inactivated A(H7N9) A/Shanghai/2/2013 virus. Several mAbs that bound H7 HA well were identified and selected for further characterization, including testing for hemagglutination inhibition and binding in Western blot under reducing and non-reducing conditions (Table 1) .
| Epitope analysis of influenza A(H7N9) monoclonal antibodies
Biolayer interferometry was used to perform epitope binning of the H7 A/Shanghai mAbs using biotinylated H7 A/Anhui/1/2013 rHA. Each mAb was captured separately to saturation, and all other mAbs were used as competing antibodies in order to examine competitive binding. As shown in 21 respectively. In several attempts at isolating escape mutants to these two mAbs, viruses with both amino acid changes (G119E and K157E) were always obtained. As shown in Figure 1 , these two amino acids are located spatially adjacent to each other on the HA, suggesting that mAbs 62 and 98 probably recognize the same HA epitope.
Cross-neutralization experiments with the escape mutant viruses and the H7 mAbs were used to extend the epitope analysis of the H7 mAbs ( each other on HA. Taken together, four distinct epitopes on the H7
HA were identified by the mAbs characterized in this study. Three epitopes, recognized by mAbs 5A6, 1E9, and 98, are located on the outer face of each HA monomer, whereas the fourth epitope recognized by mAb 7B5 is closer to the receptor-binding site of HA (Figure 1 ).
| Potency determination of A(H7N9) inactivated influenza vaccines by mAb-capture ELISA and biolayer interferometry
Monoclonal antibodies to H7 HA were used to develop a capture ELISA for quantifying the HA content of inactivated influenza A(H7N9) vaccines. The assay setup was similar to that previously described 12 and used four different H7-specific capture mAbs. ELISA all four mAbs were similar, averaging 38 μg/mL (Figure 2A ), but was approximately 57% lower than the corresponding SRID potency value of 90 μg/mL, suggesting that the mAbs did not capture this vaccine as well as the reference antigen in the ELISA format.
In the mAb-capture ELISA potency assay, HA is quantified by comparing the total amount of HA in a vaccine and a reference standard bound by the capture mAbs. However, the rate of binding to the antibody should also be dependent on the concentration of HA in the sample and can be measured by techniques such as biolayer interferometry. We explored the development of a BLI assay as another alternative assay to quantify HA in vaccine samples in comparison with a reference standard using the four H7-specific mAbs described above.
Preliminary experiments determined a loading concentration for each mAb and generated response curves to verify that the binding rate of reference antigen and vaccine samples to the mAb on the biosensor is concentration dependent (Materials and Methods).
Biolayer interferometry potency values were determined by generation of a binding rate response curve using dilutions of the reference antigen (with an assigned value of HA in μg) to each H7 mAb and comparing that standard curve to a similar binding rate response curve for each of the two inactivated vaccine samples. The potency values obtained for Vaccine 1 using the BLI-based potency assay were consistent for the four mAbs, ranging from 238 μg/mL (mAb 98) to 254 μg/ mL (mAb 1E9), and also correlated well with SRID value of 248 μg/mL for this vaccine sample ( Figure 2B) . Similarly, potency values obtained for Vaccine 2 were consistent for the four mAbs used in the assay, ranging from 109 μg/mL (mAb 5A6) to 130 μg/mL (mAb 1E9), and correlated well with the SRID value for Vaccine 2 of 90 μg/mL.
| Potency of temperature-stressed A(H7N9) A/ Shanghai vaccine
To determine whether the mAb-based ELISA and BLI assays were able to distinguish subpotent A(H7N9) vaccine and accurately quantify loss of potency, we employed heat treatment at 56°C to accelerate the decline in potency and establish conditions under which potency was significantly reduced. Aliquots of A(H7N9) Vaccine 1 were incubated at 56°C for 15 minutes, 1, 4, and 24 hours and then were assayed by SRID, as well as ELISA and BLI using 1E9, 7B5, 5A6, and 98 H7 mAbs (Table 4) . As measured by SRID, this vaccine exhibited a rapid loss of potency over time, with an 82% decline in potency after only 15 minutes at 56°C. The potency continued to decrease over time until the HA content was undetectable at 24 hours.
There was also a decline in potency as measured by ELISA and BLI using each H7 mAb. The relative potency decline measured by ELISA and BLI generally mirrored the decline in potency as measured by SRID, and the results obtained in both the ELISA and BLI analyses were similar for all four mAbs in each assay, indicating that all H7 mAbs were stability-indicating in these assays. The potency decline measured by ELISA or BLI appeared somewhat more rapid than that measured by SRID, particularly for the BLI analysis. For example, there was no detectable HA by the 4-hour time-point in the BLI analysis using any mAb. Taken together, the data show that similar heat-stressed declines in potency can be measured by all three assay platforms (SRID, ELISA, BLI) with all of the H7 mAbs and that all the platforms are capable of distinguishing temperature-stressed vaccines from unstressed vaccines.
| DISCUSSION
The SRID assay is the accepted standard for determining the potency of inactivated influenza vaccines. Importantly, the assay measures an immunogenic form of the HA antigen in the vaccine, and a link between SRID potency and vaccine immunogenicity and vaccine efficacy has been established. Nevertheless, the limitations of the SRID assay have spurred development of alternative methods to measure influenza vaccine potency. Monoclonal antibodybased potency assays also have the ability to detect and measure relevant immunogenic forms of HA, and several such promising assays have been described. However, there are at least two key issues that will have to be resolved during the development of mAb-based potency assays. One issue is the selection of the appropriate mAbs for the assay, including whether multiple antibodies are necessary to accurately assess the potency of the HA antigen in the vaccine. A second issue is whether, and how, suitable mAbs can be generated and characterized in the time frame of either seasonal or pandemic influenza vaccine manufacturing so that antibody production is not a potential bottleneck to timely vaccine manufacture.
In the current study, we began addressing these two issues in the context of mAb-based potency assays for pandemic H7 influenza vaccines that were developed following the A(H7N9) outbreak in China in 2013. Since the initial outbreak, waves of A(H7N9) virus infections in humans have reappeared each winter season, resulting in numerous human infections and deaths. 25 We generated and More recently, biolayer interferometry has emerged as an assay platform for protein quantification and its potential for determination of the potency of inactivated influenza vaccines has been proposed. 27 We used BLI to measure HA by comparing the binding of HA in vaccine samples to specific mAbs in comparison with a reference standard. In contrast to the ELISA, however, BLI measures rates of binding rather than total HA binding and does not require a detection antibody step. This method is of high throughput and is extremely fast, allowing for multiple samples and replicate assays to be run each day.
Furthermore, fewer steps are required for the BLI assay compared to the ELISA method because no additional detection steps or reagents are required, although without an additional amplification step, the BLI method is less sensitive than the ELISA. We set up the BLI assay using anti-mouse IgG Fc biosensors to bind the H7 mAbs, but other biosensor presentations for the mAbs, as well as amplification steps, are possible. Although there is far less collective experience with a BLI-based assay than ELISA-based assays for vaccine potency determination, the initial studies are encouraging and the rapid turnaround time and highthroughput capability are particularly appealing. Further studies will be needed to determine whether this type of assay can be developed as an alternative potency assay for influenza vaccines.
Encouragingly, both alternative potency assay formats using H7-specific mAbs were capable of distinguishing heat-stressed vaccine samples from non-stressed samples. Both alternative assays measure fairly rapid declines in potency when vaccine was subjected to heat treatment at 56°C and were, in fact, somewhat more sensitive to the heat treatment than the SRID assay (e.g, 1-and 4-hour time-points).
Future studies will be needed to further define the most appropriate methods for assessing the stability-indicating capabilities of alternative assays, and this will be an important component of the evaluation and selection of antibodies for any mAb-based assay.
In summary, the results of the current study broaden our understanding of the issues that must be resolved as development of mAbbased alternative potency assay for influenza vaccines progresses.
Although the preparation and characterization of strain-specific mAbs will be a challenge, the results from this and other recent studies demonstrate that development and selection of cross-reactive mAbs is a realistic possibility. Advanced development and preparation of a well-characterized, diverse panel of mAbs that recognize different HA epitopes for influenza subtypes with pandemic potential, such as the H7 mAbs described in the present study, greatly increase the probability of having mAbs available for vaccine testing as influenza strains evolve.
